H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

FY 2024 revenue of $228.4 million, in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting ...

FY 2024 revenue of $228.4 million, in-line with company guidance <li /> Commercial Cell & Gene Therapy revenue rose to $26 million in FY ...

The stock market kicked off the trading week in a bloodbath, erasing last week’s gains, with all major indices posting heavy ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...

In the report, ImmunityBio discusses its significant developments, including receiving a J-code for Anktiva in the U.S., ...

US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare ...

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva ...

We recently compiled a list of the Wall Street Optimism Spills Over to These 10 Stocks on Friday. In this article, we are ...

Culver City, California Saturday, March 1, 2025, 17:00 Hrs [IST] ...